Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
REGROTON vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension
Hypertension
1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life: 9-11 hours (mean 10 hours); clinical context: supports once-daily dosing in hypertension, steady-state reached in 3-4 days
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Reserpine is extensively metabolized in the liver via hydrolysis and conjugation; chlorthalidone is metabolized minimally, mainly excreted unchanged in urine, with some hepatic conjugation.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal: 70-80% (50% as unchanged drug, 20-30% as metabolites); Fecal: <5%
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Reserpine: 96% bound to albumin and alpha-1-acid glycoprotein; Chlorthalidone: 75% bound to erythrocytes (carbonic anhydrase) and 75% to plasma proteins (albumin)
~90%, primarily to albumin
Reserpine: 2.5-3.5 L/kg; Chlorthalidone: 3-4 L/kg; clinical meaning: extensive tissue distribution with prolonged effect due to reserpine's irreversible binding to adrenergic neurons
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: reserpine 30-50%; chlorthalidone 64%
Oral: 50–60% (extensive first-pass metabolism)
GFR 30-60 m L/min: use with caution; GFR <30 m L/min: contraindicated.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh Class A/B: reduce metoprolol dose by 50%; Class C: avoid use.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not recommended for use in pediatric patients.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate at half the standard dose (25 mg chlorthalidone/25 mg metoprolol) and titrate slowly due to increased risk of hypotension and electrolyte imbalance.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
May cause depression, particularly in patients with history of depression; discontinue if signs appear.,Electrolyte imbalance (hypokalemia, hyponatremia) due to chlorthalidone.,Bradycardia and orthostatic hypotension.,Use cautiously in patients with renal impairment, gout, or diabetes.,Possible increased risk of breast cancer with long-term reserpine use.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to reserpine, chlorthalidone, or sulfonamides (chlorthalidone is a sulfonamide).,Active peptic ulcer disease.,History of mental depression (especially with suicidal tendencies).,Anuria or severe renal impairment.,Electrolyte depletion (untreated hypokalemia, hypercalcemia).
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid high-potassium foods and salt substitutes (e.g., bananas, oranges, spinach, potassium-containing salt substitutes) due to risk of hyperkalemia with chlorthalidone. Limit alcohol intake. Maintain adequate hydration but avoid excessive fluid intake. Grapefruit juice may increase atenolol absorption; limit intake. Take with food to reduce GI upset.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiac anomalies, and oral clefts due to chlorthalidone; potential for fetal hypotension and oligohydramnios. Second and third trimesters: fetal hypotension, oligohydramnios, intrauterine growth restriction, and neonatal complications including electrolyte imbalances, thrombocytopenia, and jaundice. Avoid use in pregnancy, especially during second and third trimesters.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Chlorthalidone and reserpine are excreted into breast milk. Chlorthalidone M/P ratio not established; reserpine M/P ratio approximately 0.5. Use with caution due to potential for adverse effects in the nursing infant, including electrolyte disturbances and cardiac effects. Generally not recommended during breastfeeding.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No specific dose adjustments established. Due to increased plasma volume and renal clearance, efficacy may be reduced; however, risks generally outweigh benefits. Consider alternative antihypertensives. If used, start at lowest effective dose and monitor closely for electrolyte imbalances and hypotension.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
REGROTON is a fixed-dose combination of chlorthalidone (a thiazide-like diuretic) and atenolol (a cardioselective beta-blocker). Monitor for hypokalemia, hyperuricemia, and glucose intolerance from chlorthalidone. Atenolol may mask tachycardia in hypoglycemia and cause bradycardia; avoid abrupt discontinuation. Dosing adjustment needed in renal impairment (Cr Cl <30 m L/min contraindicated). Caution in COPD/asthma bronchospasm, peripheral vascular disease, and heart failure.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed, usually once daily, preferably in the morning to avoid nocturia.,Do not stop taking abruptly; sudden discontinuation may cause chest pain or palpitations.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or excessive thirst.,Check blood pressure and pulse regularly; keep a log.,Avoid alcohol, which can increase blood pressure lowering effects and cause dizziness.,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Inform your doctor if you develop shortness of breath, wheezing, swelling, or unusual weight gain.,This drug may increase blood sugar; monitor glucose if diabetic.,Use sunscreen and protective clothing; medication can increase sun sensitivity.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about REGROTON vs ALDORIL 15, answered by our medical review team.
REGROTON is a Antihypertensive Combination that works by Regroton is a combination of reserpine and chlorthalidone. Reserpine depletes catecholamines from peripheral sympathetic nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to vasodilation and reduced heart rate. Chlorthalidone is a thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between REGROTON and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of REGROTON is: 1 tablet (25 mg chlorthalidone / 50 mg metoprolol) orally once daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between REGROTON and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. REGROTON is classified as Category C. Pregnancy Category D. First trimester: increased risk of neural tube defects, cardiac anomalies, and oral clefts due to chlorthalidone; potential for fetal hypotension and oligohyd. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.